Open AccessPrognostic impact of gene copy number instability and tumor mutation burden in patients with resectable gastric cancer
Author(s) -
Cai Lisheng,
Li Linhai,
Ren Dandan,
Song Xue,
Mao Beibei,
Han Bo,
Zhang Henghui
Publication year - 2020
Publication title -
cancer communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.119
H-Index - 53
ISSN - 2523-3548
DOI - 10.1002/cac2.12007
Subject(s) - medicine , capecitabine , oncology , oxaliplatin , cancer , gastrectomy , chemotherapy , targeted therapy , performance status , colorectal cancer
Dear Editor, Gastric cancer (GC) is a leading cause of cancer-related deaths worldwide, especially in China and other East Asian countries [1, 2]. Although considerable achievements have been made in its treatment [3] and predictive biomarkers [4] in past decades, the prognosis of GC remains poor [5]. Therefore, more effective prognostic markers are needed to improve the prognosis prediction of GCs. Small panels based on next-generation sequencing, such as FoundationOne CDx and MSK-IMPACT, are widely used for selecting appropriate treatment approaches (such as targeted therapies, immunotherapies, and chemotherapies) with the advantages of a higher sequencing depth and more cost-effectiveness than whole-exome sequencing (WES). Previous studies have demonstrated that molecular characteristics based on the designed cancer-related gene panel were consistent with those determined by WES and could be prognostic markers for various cancer types [6-8]. As such, we analyzed the molecular features with the designed panel to investigate probable prognostic biomarkers for Chinese patients with GC. We selected 100 patients who underwent surgery and histologically diagnosed with GC. Of the 100 patients, 70 were diagnosed at Zhangzhou Affiliated Hospital of Fujian Medical University and classified as the discovery set; 30 were diagnosed at the First People’s Hospital of Yunnan Province and were regarded as the validation set. Eighty-nine patients underwent radical gastrectomy, and 11 underwent palliative gastrectomy. Primary and paired adjacent paracancerous tissue samples collected during surgery were used for sequencing. All patients had undergone adjuvant chemotherapy with capecitabine plus oxaliplatin (XELOX). The median number of chemotherapy cycles was 6 (range, 3-12). Overall survival (OS) was defined as the time from surgery to death or the last follow-up. The median follow-up time was 37.3 months (range, 6.0-91.1 months), and 71 patients died during